Conoya Biopharma Technology

Conoya Biopharma is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the discovery and development of innovative antibody-based therapeutics. The company focuses on addressing significant unmet medical needs in the fields of immunology and oncology through its proprietary nCO-Mab platform. Its lead candidate, CM310, is a humanized monoclonal antibody targeting the IL-4Rα subunit, currently being evaluated for various allergic diseases such as atopic dermatitis and asthma. Additionally, Conoya is advancing a robust pipeline of bispecific antibodies and monoclonal antibodies targeting Claudin 18.2 and other validated oncology targets. By leveraging its internal R&D capabilities, the company aims to deliver high-quality biologics to patients globally.